In 2023, Dr. Matthew B. Klein earned $1.22M in total compensation at PTC Therapeutics, primarily from $747.22K salary. Most recently sold 15,584 shares in Feb 2025. Currently holds stock worth $27.72M. 2+ years at the helm of PTC Therapeutics.
Compensation History
Annual executive compensation data for Dr. Matthew B. Klein, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.22M
Salary
$747.22K
Bonus
$0.00
Other
$472.80K
Salary
$747.22KBoard Justification
The compensation philosophy is to align executive compensation with company performance and shareholder interests, with a significant portion being 'at risk'.
Bonus
$0.00Board Justification
No bonus was awarded for 2023 as the corporate rating was 80% of target and individual performance modifier was 1.0, resulting in a cash incentive of $472,800 based on corporate performance.
Other Compensation
$472.80KBoard Justification
Includes the cash awards earned under the annual incentive program based on corporate performance.
Restricted Stock
Board Justification
No stock was vested in 2023 as the stock options and RSUs granted in 2023 have not yet vested.
Performance Metrics
The performance metrics for 2023 included achieving corporate goals related to financial performance, commercial success, advancing programs and pipelines, and operational excellence.
Dr. Matthew B. Klein
CEO of PTC Therapeutics
Education
BA from the University of Pennsylvania, MD from Yale University School of Medicine, MS in Epidemiology from the University of Washington School of Public Health
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
Born
January 1, 1972 - 53 years ago
CEO of PTC Therapeutics for
2 years 8 months (Mar 2023 - Present)
Previous Experience
Chief Operating Officer at PTC Therapeutics, Inc.; formerly CEO of BioElectron Technology Corporation.
Other PTC Therapeutics CEOs
Holdings
Track Dr. Matthew B. Klein's stock holdings and portfolio value over time.
Total Stock Sold
$3.40M
$3.40M
75,179 PTCT shares
What if they kept their stock?
If Dr. Matthew B. Klein didn't sell their stock, today they would have:
Extra PTCT75,179 shares worth $5.81M.
This is 70.64% and $2.40M more than what they got when they sold the stock.
Insider Trading
Dr. Matthew B. Klein's recent stock transactions, purchases, and sales filed with the SEC.
$780.91K
PTCT at $50.11/share
Feb 19, 2025
Sale
$204.12K
PTCT at $44.92/share
Jan 7, 2025
Sale
70,000 shares
PTCT
Jan 3, 2025
Received
$373.88K
PTCT at $45.16/share
Dec 31, 2024
Sale
$83.67K
PTCT at $24.89/share
Apr 19, 2024
Sale
$32.85K
PTCT at $25.14/share
Apr 17, 2024
Sale
70,000 shares
PTCT
Feb 15, 2024
Received
$221.40K
PTCT at $28.83/share
Jan 8, 2024
Sale
$274.39K
PTCT at $27.15/share
Jan 5, 2024
Sale
75,000 shares
PTCT
Dec 28, 2023
Received
Rivals
Compare Dr. Matthew B. Klein with competitor CEOs and industry peers.